Ensure she gets the most appropriate breast cancer therapy: Test for PITX2
Find out more
PITX2 methylation: A novel biomarker for breast cancer chemotherapy selection
QIAGEN supports education and awareness of cutting-edge approaches to improve treatment and increase testing of breast cancer patients. Discover how PITX2 methylation can be used to predict response of breast cancer patients to anthracycline-based chemotherapy.
Read more
Test for PITX2 methylation to select the right chemotherapy for high-risk breast cancer patients
The therascreen PITX2 RGQ PCR Kit is the first assay to provide a clinically validated methylation cut-off value to determine the most beneficial therapy for high-risk breast cancer patients. Find out how you can use this new PITX2 assay to increase your testing portfolio.
Start PITX2 testing
Reliably detect BRCA 1/2 germline or somatic mutations or deletions for breast and ovarian cancer research
Find out more about our NGS solution for oncology research. Our BRCA 1/2 panel is integrated into a complete Sample to Insight NGS workflow, including bioinformatics analysis and interpretation.
find out more!
The tools you need to ensure patients receive the best individualized care
QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.
browse our products!